Calendario›REGN›REGN7544 · PINNACLE

REGN7544 · PINNACLE

Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)

Ensayo de REGENERON PHARMACEUTICALS, INC. en Postural Orthostatic Tachycardia Syndrome (POTS) (del registro, en inglés).

Fase

Fase 2

Estado

Completado

Participantes

82

previstos

Centros

16

Fin del objetivo primario

may 2026

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en nov 2024.

Qué mide

Change in Heart Rate (HR) from supine to standing (DeltaHR) (del registro, en inglés) (en el dia 8)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on participants with POTS. The aim of the study is to see how safe, tolerable, and effective the study drug is. The study is looking at several other research questions, including: * How the study drug changes heart rate and blood pressure in participants with POTS * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * How the study drug affects symptoms associated with POTS

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06593600), actualizada en jul 2026.